Why the study?
Progressive cardiac fibrosis leads to ventricular wall stiffness, dysfunction, and heart failure, but the role and underlying mechanisms of PDCD5 in cardiac fibrosis remain largely unknown.
Does PDCD5 overexpression reduce cardiac fibrosis and improve cardiac function post-myocardial infarction?
Population
Patients with cardiac fibrosis, post-myocardial infarction mice, and stimulated cardiac fibroblasts
Comparison
PDCD5 overexpression, protein treatment, or knock-in vs knockdown, control, or HDAC3 overexpression
Design
Preclinical laboratory and animal study
Key result
PDCD5, upregulated by SMAD3, ameliorated progressive cardiac fibrosis and cardiac dysfunction post-myocardial infarction by promoting HDAC3 ubiquitination and inhibition.
Authors
Loading...
May support PDCD5 modulation to limit post-MI fibrosis; hypothesis-generating in animal models and requires clinical validation.
Does PDCD5 overexpression reduce cardiac fibrosis and improve cardiac function post-myocardial infarction?
PDCD5 acts as a negative feedback factor on fibrotic signaling pathways and may be a potential therapeutic target to suppress cardiac fibrosis post-myocardial infarction.
Weng et al. (2023) studied Cardiac fibrosis post-myocardial infarction. PDCD5 overexpression or knock-in vs. Control, PDCD5 knockdown, or HDAC3 overexpression was evaluated on Cardiac fibrosis and cardiac function. PDCD5, upregulated by SMAD3, ameliorated progressive cardiac fibrosis and cardiac dysfunction post-myocardial infarction by promoting HDAC3 ubiquitination and inhibition.